Multiple Sclerosis

Mar 07, 2019

Biogen to buy Nightstar for USD 800 Million Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar. The deal will let Biogen have access to two experimental gene therapies for blindness-causing diseases helping Biogen’s pipeline. Pacira...

Nov 12, 2018

Could a virus be a treatment therapy? Confusing, isn't it? On the face value, it seems no; but on delving deeper, the confusion dissipates. There have been tireless efforts among a section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer ...

Mar 12, 2018

Celiac Disease (Gluten-Sensitive Enteropathy) is a chronic, autoimmune, inflammatory disease of the small intestine characterized by damage to the lining of the small intestine and typically leads to dyspepsia, malabsorption and a variety of other symptoms. Individuals with Celiac Disease carry DQ2 or DQ8 MHC class ...

Apr 04, 2017

Biogen triumphs in latest Tecfidera patent dispute Biogen has prevailed in a patent squabble with Denmark’s Forward Pharma over multiple sclerosis med Tecfidera—but the decision may not actually help the Big Biotech steer clear of generic rivals. The Patent Trial and Appeal Board (PTAB) ruled Friday that Forward cou...

Mar 30, 2017

Mylan closing Illinois plant, cutting 90 jobs as part of slim-down after Meda buyout Mylan has been in the midst of cutting about 3,500 jobs to decrease costs and refocus after its $7 billion buyout last year of Meda Pharmaceuticals. About 90 of those cuts will come with the closure of a plant in Illinois.The drugma...